Siegfried Holding Ltd’s shares fell 5.3% to CHF 76 in midday trading on Thursday, extending losses after UBS downgraded the Swiss contract development and manufacturing organization (CDMO) to Neutral from Buy.
The stock opened at CHF 78.35 and touched a session low of CHF 73.60, leaving it well below its 52-week high of CHF 101.60 and near the annual low of CHF 65.05. The broader market showed modest declines, with the S&P 500 down 0.1% and the Nasdaq falling 0.5%.
UBS analyst Tanya Hansalik reduced her price target on Siegfried to CHF 80 from CHF 120 and trimmed earnings-per-share estimates for 2026 through 2028 by about 7%. RBC Capital also cut its price target, adding pressure to the shares.
The downgrade follows Siegfried’s first-half 2026 results, released on August 21, which showed mixed performance. Drug substances net sales rose 4.8% in local currencies to CHF 431.1 million, while drug products net sales increased 1.5% to CHF 201.9 million. Core EBITDA grew 6.0% to CHF 142 million, lifting the core EBITDA margin to 22.4%. Full-year guidance was maintained, though analysts noted an implied acceleration of 9%–13% in the second half, concentrating execution risk in the period ahead.
Investor sentiment has soured amid concerns over slower-than-anticipated ramp-up of new production capacity and weaker-than-expected revenue from a recently acquired US business. The decline also unwinds a brief post-results relief rally earlier in the week, as skepticism persists over the sustainability of the company’s back-loaded 2026 growth profile.
